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Nonbacterial thrombotic endocarditis (NBTE) is a rare clinical condition characterized by the presence of sterile vegetations on
valvular leaﬂets Gross and Friedberg (1936). The most frequent cause of NBTE is antiphospholipid syndrome Hughson and et
al. (1993); malignancy, through an intrinsic condition of hypercoagulability, is the second most common cause Thomas (2001).
Systemic thromboembolic complications are frequently associated with this condition, but coronary embolism is not common.
We report the case of a patient with NBTE secondary to gastric adenocarcinoma with clinical symptoms of coronary and systemic
emboli.
1.CaseReport
A 43-year-old previously healthy woman presented with
sudden onset of substernal chest pain that had begun some
hours earlier. She had no history of coronary artery disease.
Physical examination revealed pulse 98beats/min and blood
pressure 95/60mm, Hg. Electrocardiogram (ECG) showed
ST segment elevation in leads II, III, AVF (Figure 1).
Myocardial infarction was diagnosed and the patient was
admitted to the coronary care unit, where a coronary
angiogramdemonstrateddistalocclusionoftheinterventric-
ular posterior artery. The following day, the patient devel-
opeddysarthria,right-sidedweakness,andlefthomonymous
quadrantanopsia. Brain magnetic resonance imaging (MRI)
showed several scattered cortical infarcts in the left parieto-
occipital region. A transesophageal echocardiogram (TEE),
performed to evaluate the neurologic symptoms, revealed
on the atrial surface of the mitral valve a 0.7cm by 1cm
echodense mass on the anterior leaﬂet (Figure 2)a n da
0.6cm by 0.5cm vegetation on the posterior leaﬂet, with
evidence of moderate mitral regurgitation. Low-molecular-
weight heparin therapy was started. The patient remained
afebrileandserialbloodcultureswerenegative.Bloodstudies
revealed moderate thrombocytopenia (50–70.000 per mm3),
leukocytosis (20.000 per mm3), and normal hematocrit.
Extensive evaluation, including antiphospholipid antibodies,
antinuclear antibody, and antineutrophil cytoplasmic anti-
body, revealed nothing signiﬁcant. Meanwhile, the patient
complained of nausea and persistent vomiting; also an
elevated plasma level of CA-19.9 was detected: as a result,
a ﬁberoptic gastroscopy with biopsy was performed. This
revealed the presence of a 4cm by 3cm mass on the lesser
curvature, identiﬁed as a gastric adenocarcinoma at the
pathological examination. A total-body contrast-enhanced
computed tomography showed multiple splenic and renal
infarcts but failed to detect any metastatic lesion.
Consequently, the patient was promptly scheduled for
a gastrectomy but suddenly developed a right-sided facial
droop and further visual disturbances. A second TEE
demonstrated persistence and enlargement of the two veg-
etations previously seen on the mitral leaﬂets, in spite
of the anticoagulant therapy which had been promptly
started. Therefore priority was given to valvular surgery
and the patient underwent mitral valve replacement with
a bioprostheses without complications. At surgery, the
echocardiographic preoperative ﬁndings were conﬁrmed2 Cardiology Research and Practice
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Figure 1: Ecg on admission reveals ST segment elevation in leads II, III, AVF.
Figure 2: Transesophageal echocardiography shows an echodense
structure (0.7cm by 1cm) on the atrial aspect of the anterior mitral
leaﬂet.
(Figure 3). The pathological examination of the excised
valve revealed that the vegetations were made up of ﬁbrin
and blood platelets; negative stain and cultures conﬁrmed
them to be sterile. Granulation tissue and active enlarged
ﬁbroblasts were found in the leaﬂet tissue, at the implant site
of the vegetations and all around. On the 10th post-operative
day the patient underwent a subtotal gastrectomy and was
discharged seven days later.
2. Discussion
NBTE is characterized by the formation of vegetations on
heart valves in the absence of systemic bacterial infections.
The vegetations are made up of ﬁbrin and blood platelets
and the valvular tissue is either normal or shows some
evidence of inﬂammatory response. As to the pathogenesis,
it has been suggested that NBTE could result from local
valvular damage mediated by elevated levels of circulating
cytokines (such as tumor necrosis factor or interleukin-1).
It may also result from the well-known hypercoagulable state
associated with malignancies (increased levels of factor VIII,
Figure 3: Arrows point to the vegetations on the leaﬂets.
ﬁbrinogen, and von Willebrand factor) [1]. A pre-existing
valvular lesion is considered a signiﬁcant predisposing factor
in the pathogenesis of NBTE [1–5].
The incidence of NBTE is uncertain. However, in three
largeautopsyseriespublishedoverthelast30years[6]NB TE
has shown an incidence ranging between 1% and 1,6%.
In these cases an underlying malignancy was found with
a frequency varying between 32% and 80%. On the other
hand, an echocardiographic study of 200 living patients with
various cancers found evidence of NBTE in approximately
19% [7].
The major clinical manifestations of NBTE result from
systemic emboli rather than valvular dysfunction. In the
great majority of these patients an embolism occur specially
in the spleen, the kidneys, or the central nervous system
[6] and can be the main cause of morbidity. In case
of coronary embolism, if a pre-existing coronary artery
disease has not led to the formation of a collateral coronaryCardiology Research and Practice 3
circulation, sudden disruption of the blood supply can cause
more myocardial damage and a poorer prognosis, and a
thrombolytic therapy could therefore seem advisable. How-
ever, in case of NBTE, in which sterile valvular vegetations
made up of ﬁbrin and platelets are the potential source of
coronary embolism, we believe that a thrombolytic therapy,
in a similar way as in the patients aﬀected with prosthetic
mechanical valve thrombosis, could face a high risk of
thromboembolism and ischemic stroke, or to a lesser extent,
of major bleeding episodes [8, 9] and must therefore be
conﬁned to selected cases.
Treatment of NBTE includes systemic anticoagulation to
prevent recurrent thromboembolism. However, in patients
with malignancy-related NBTE, warfarin is often ineﬀective,
probably because of the presence of some nonvitamin K-
dependent procoagulant agents which relate to the under-
lying neoplasm [10] and should not be used. In these
cases use of heparin or low-molecular-weight heparin is
recommended.
The indications and appropriate timing of surgical
therapyinNBTEhavenotbeenformallyevaluated.However,
in patients with cancers that are potentially curable, the
recurrence of embolic events despite anticoagulation and the
presence of valvular dysfunction could suggest the need to
give priority to the cardiac procedure.
In the case reported, clinical presentation was unusual:
at the onset, embolism ﬁrst aﬀected coronary circulation,
with electrocardiographic and clinical signs of acute inferior
myocardial infarction, and later central nervous system. On
the basis of the recurrent embolic events registered (despite a
correct anticoagulant therapy) and given that the underlying
gastric cancer was considered curable, a preliminary valvular
surgery seemed advisable.
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